Skip to search formSkip to main contentSkip to account menu

SEN0014196

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Biochemical mechanism and biological effects of the inhibition of silent information regulator 1 (SIRT1) by EX-527 (SEN0014196 or selisistat)
Abstract The human sirtuin silent information regulator 1 (SIRT1) is a NAD+-dependent deacetylase enzyme. It deacetylates many… 
2013
2013
A randomized, double-blind, placebo-controlled phase Ib study with selisistat (SEN0014196) in patients with Huntington's disease
2012
2012
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IB PHARMACODYNAMIC STUDY WITH SELISISTAT (SEN0014196) IN HD PATIENTS
2012
2012
F02 Selisistat: soluble HTT protein levels as a potential pharmacodynamic readout
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat… 
2012
2012
FROM BIOLOGY TO THE BEDSIDE-SIRTUINS AS TARGETS FOR DISEASE MODIFICATION IN HUNTINGTON'S DISEASE: SELISISTAT PRECLINICAL DATA AND PRELIMINARY PHASE I RESULTS
To date no disease modifying therapy has shown efficacy in Huntington's Disease (HD). The PADDINGTON (Pharmacodynamic Approaches… 
2012
2012
F04 Selisistat: potential pharmacodynamic readouts based on transcriptomics
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selisistat… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)